# Cocoa Flavanols (High-Flavanol Extract) - Clinical Longevity Review & Consensus Audit

> **Consensus Verdict**: COSMOS large-scale clinical trial and cognitive studies validate cardiovascular death reduction and flow-mediated dilation improvement.

## 1. Executive Summary & Scores
- **Longevity Evidence Score**: **90/100**
- **Evidence Quality Tier**: **silver**
- **Human Clinical Evidence Strength**: 90/100
- **Primary Longevity Classification**: supplements
- **Safety Margin Score**: 84/100 (Higher is safer)
- **Time Burden**: ~15 minutes/day
- **Estimated Monthly Cost**: inexpensive
- **Adherence Friction**: 3/10 (Lower is easier to sustain)

---

## 2. Biological Mechanisms of Action
eNOS phosphorylation and Akt pathway stimulation

---

## 3. Canonical Longevity Vector Impacts (The 8 Longevity Pillars)

---

## 4. Practical Protocol & Administration Guidelines
- **Standard Clinical Dosage**: 500 mg – 1,000 mg flavanols
- **Recommended Timing**: Dinner / Evening
- **Administration Type**: supplement
- **Recommended Biomarkers to Monitor**: brain_fog, heart_health

---

## 5. Safety, Contraindications & Drug Interactions
- **Contraindications**: Severe hypotension
- **Safety Profile**: Very High - Extremely safe; check for low caffeine content if taken late evening.

---

## 6. Peer-Reviewed Human Clinical Trials & Key PMIDs
1. **Cocoa Flavanols Enhance Dentate Gyrus Function and Memory in Older Adults** [PMID: 25348813]
   - Link: https://pubmed.ncbi.nlm.nih.gov/25348813/
2. **Effect of Cocoa Flavanol Supplementation on Cardiovascular Events (COSMOS Trial)** [PMID: 35294962]
   - Link: https://pubmed.ncbi.nlm.nih.gov/35294962/
3. **Effect of Cocoa Flavanol Supplementation for the Prevention of Cardiovascular Events: The COSMOS Randomized Clinical Trial** [PMID: 35293444]
   - Link: https://pubmed.ncbi.nlm.nih.gov/35293444/

---

## 7. Canonical Citation & Web Verification
- **Official Web Review**: [Cocoa Flavanols (High-Flavanol Extract) on LongevityReviews](https://longevityreviews.org/modalities/cocoa-flavanols)
- **Last Evidence Calibration**: 2026-08-09
- **Review Policy**: 0% sponsored placements, independent peer-reviewed consensus.